{"pressReleaseArticle":{"contentWrapper":{"title":"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis","intro":"<p>GSK today announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA).</p>","publishDateTime":"25/11/2015 00:00:00","publishDate":"25 November 2015","forInvestorsAndMediaOnlyText":"","shortDescription":"GSK announced that dosing has commenced in a phase III study evaluating sirukumab.","image":null,"downloadLink":null,"tags":[]},"components":[{"type":"rich-text","text":"<p>Issued: Wednesday 25 November 2015, London UK</p>\n<p>GSK today announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA).</p>\n<p>GCA, a disease characterised by inflammation of large and medium sized arteries predominantly in the head and neck, occurs in people aged 50 years or over. Patients typically experience severe headache, visual loss, jaw and muscular pain and may be at risk of permanent sight loss if not treated promptly. The mainstay of treatment is with high doses of steroids to rapidly reduce the inflammation and prevent sight loss. In order to minimise side effects that can occur with high doses and long term use, steroids are tapered after remission to lower maintenance doses. However, disease relapse is common during steroid taper and remission with steroids is often followed by subsequent relapse requiring repeat high dose treatment. As a result over 70% of patients experience significant side effects from steroids such as osteoporosis, cataract, hypertension and type 2 diabetes mellitus.</p>\n<p>The phase III randomised, double-blind, placebo-controlled study (named the “SIRRESTA” study) will evaluate the efficacy and safety of two subcutaneous doses of sirukumab (100mg every two weeks and 50mg every four weeks) with a pre-specified tapering dose of prednisone for the treatment of GCA.  This approach will specifically answer whether treatment with sirukumab can reduce the duration of steroid treatment typical in clinical practice. The study comprises two distinct parts: a 52 week double-blind treatment phase (Part A) and a 104 week long term extension phase (Part B).  The primary endpoint of the study is the proportion of patients that achieve sustained remission.</p>\n<p>Paul-Peter Tak, Senior Vice President, GSK Immuno-Inflammation R&amp;D, said: “The use of high dose steroids to treat giant cell arteritis can cause severe side effects with prolonged use. Alternative treatments are required and we believe sirukumab could be an important option for patients with this disease. The start of our study with sirukumab for GCA, which is currently under investigation for rheumatoid arthritis, marks the progress we are making to apply our knowledge of the underlying cause of a variety of immune-mediated inflammatory diseases and explore the potential of our immuno-inflammation pipeline to treat multiple conditions.”</p>\n<p>Sirukumab is not approved as a treatment for any indication anywhere in the world.</p>\n<p><strong>About Sirukumab</strong></p>\n<p>Sirukumab is an investigational human anti-IL-6 monoclonal antibody that selectively binds with high affinity to the IL-6 cytokine, a naturally occurring protein that is believed to play a role in autoimmune conditions. It is in phase III development for rheumatoid arthritis (RA) and GCA.</p>\n<p>As part of a collaboration with Janssen Biologics (Ireland) [Janssen], a phase III programme began in August 2012 to investigate sirukumab for the treatment of moderately to severely active RA.  The licensing and co-development collaboration agreement, which was entered into by GSK and Janssen in December 2011, gives both companies the option to investigate sirukumab for other indications beyond RA.</p>\n<p>The Phase III study investigating sirukumab for GCA is fully funded and sponsored by GSK. Janssen has the right to opt into the GCA programme at any stage of development.</p>\n<p><strong>About Giant Cell Arteritis</strong></p>\n<p>Giant Cell Arteritis (GCA) is a type of vasculitis (inflammation of blood vessels) which results in inflammation of large and medium-sized arteries. The inflammation can inhibit blood flow which can cause damage to the body's organs. It is the most common form of vasculitis in the United States and Europe. In addition to the first line use of steroids, patients that relapse may also require glucocorticoid-sparing agents to help reduce the dose of steroids. Many patients experience significant side effects as a result of long term steroid treatment.</p>\n<p class=\"MainBodycopy\"><strong>GSK</strong> – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit our <a href=\"/en-gb/about-us/\" title=\"About us\">about us section</a>.</p>\n<p class=\"MainBodycopy\"> </p>\n<table cellspacing=\"0\" cellpadding=\"0\">\n<thead></thead>\n<tbody>\n<tr>\n<td width=\"191\">\n<p><strong>GSK enquiries:</strong></p>\n</td>\n<td width=\"155\">\n<p> </p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\"> </p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\"> </p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> UK Media enquiries:</p>\n</td>\n<td width=\"155\">\n<p>Simon Steel</p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\">+44 (0) 20 8047 5502</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\">(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>David Daley</p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\">+44 (0) 20 8047 5502</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\">(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>Namrata Taak</p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\">+44 (0) 20 8047 5502</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\">(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p> </p>\n</td>\n<td width=\"151\">\n<p> </p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p>US Media enquiries:</p>\n</td>\n<td width=\"155\">\n<p>Sarah Alspach</p>\n</td>\n<td width=\"151\">\n<p>+1 202 715 1048</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(Washington, DC)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>Sarah Spencer</p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\">+1 215 751 3335</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\">(Philadelphia)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>Mary Anne Rhyne</p>\n</td>\n<td width=\"151\">\n<p>+1 919 483 0492</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(North Carolina)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p> </p>\n</td>\n<td width=\"151\">\n<p> </p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p>Analyst/Investor enquiries:</p>\n</td>\n<td width=\"155\">\n<p>Ziba Shamsi</p>\n</td>\n<td width=\"151\">\n<p>+44 (0) 20 8047 5543</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>Tom Curry</p>\n</td>\n<td width=\"151\">\n<p>+ 1 215 751 5419</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(Philadelphia)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p class=\"Tabletext9\"> </p>\n</td>\n<td width=\"155\">\n<p>Gary Davies</p>\n</td>\n<td width=\"151\">\n<p class=\"Tabletext9\">+44 (0) 20 8047 5503</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p class=\"Tabletext9\">(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>James Dodwell</p>\n</td>\n<td width=\"151\">\n<p>+44 (0) 20 8047 2406</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(London)</p>\n</td>\n</tr>\n<tr>\n<td width=\"191\">\n<p> </p>\n</td>\n<td width=\"155\">\n<p>Jeff McLaughlin</p>\n</td>\n<td width=\"151\">\n<p>+1 215 751 7002</p>\n</td>\n<td width=\"119\" valign=\"top\">\n<p>(Philadelphia)</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p> </p>\n<table cellspacing=\"0\" cellpadding=\"0\">\n<thead></thead>\n<tbody>\n<tr>\n<td width=\"616\">\n<p><em>Cautionary statement regarding forward-looking statements</em><br><em>GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.</em></p>\n</td>\n</tr>\n</tbody>\n</table>","useGreyBackground":false,"fullWidth":false}]},"id":7913,"docCheckLogout":null,"pageType":"pressReleasePage","languageCode":"en-GB","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-gb/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Press releases","href":"/en-gb/media/press-releases/","openInNewWindowText":null},{"text":"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis","href":"/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/","openInNewWindowText":null}]},"pageName":"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-gb/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":true,"text":"Global"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark mode","tooltipText":"<p>Switch to dark mode to head towards a more sustainable world together. <a href=\"/en-gb/digital-sustainability/#\" title=\"Digital sustainability\" data-anchor=\"#\">More info</a></p>"},"globalSiteLink":null,"locationSelector":{"text":"Change location","href":"/en-gb/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science magazine","url":"/en-gb/behind-the-science-magazine/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-gb/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-gb/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"GSK at a glance","url":"/en-gb/company/gsk-at-a-glance/","nodes":[],"isActive":false},{"title":"History and heritage","url":"/en-gb/company/history-and-heritage/","nodes":[],"isActive":false},{"title":"Board of Directors and Executive Committee","url":"/en-gb/company/board-of-directors-and-leadership-team/","nodes":[],"isActive":false},{"title":"Board information","url":"/en-gb/company/board-information/","nodes":[],"isActive":false},{"title":"Governance","url":"/en-gb/company/governance/","nodes":[{"title":"Committees","url":"/en-gb/company/governance/committees/","nodes":[],"isActive":false},{"title":"Shareholders","url":"/en-gb/company/governance/shareholders/","nodes":[],"isActive":false},{"title":"Sarbanes-Oxley Act 2002","url":"/en-gb/company/governance/sarbanes-oxley-act-2002/","nodes":[],"isActive":false},{"title":"Compliance","url":"/en-gb/company/governance/compliance/","nodes":[],"isActive":false}],"isActive":false},{"title":"Policy positions","url":"/en-gb/company/policy-positions/","nodes":[],"isActive":false},{"title":"Codes, standards and reports","url":"/en-gb/company/codes-standards-and-reports/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Our purpose, strategy and culture","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=100&v=1dba2ec0bc1e680&hmac=13d78c5b371b5e09f560d958dfb6a3b8cb27a35b1578669ba061acc1b12273dd","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=50&v=1dba2ec0bc1e680&hmac=7971e77f08fa2cbbfcb2e6dff5010e3d9c37f8561060dfbcdc7ec38ac7e5f314","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0&hmac=9e8e9da5bd3ca0619cfd47c6274f5ecbae61a5b73808bbd57b4fdffa469f2037","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0&hmac=25f6331ff89b8ea1f896e23e1cc935cee241b346efb1b08bd5aa5b5aa0d4e09c","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/careers/outstanding-people/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-gb/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-gb/innovation/therapeutic-areas/","nodes":[{"title":"Respiratory, immunology and inflammation","url":"/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-gb/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/en-gb/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-gb/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"Our leading scientists","url":"/en-gb/innovation/our-leading-scientists/","nodes":[{"title":"Dr Tony Wood","url":"/en-gb/innovation/our-leading-scientists/tony-wood/","nodes":[],"isActive":false},{"title":"Dr Sabine Luik","url":"/en-gb/innovation/our-leading-scientists/sabine-luik/","nodes":[],"isActive":false},{"title":"Dr Hesham Ahmed Abdullah","url":"/en-gb/innovation/our-leading-scientists/hesham-abdullah/","nodes":[],"isActive":false},{"title":"Dr Kaivan Khavandi","url":"/en-gb/innovation/our-leading-scientists/kaivan-khavandi/","nodes":[],"isActive":false},{"title":"Dr Christopher Austin","url":"/en-gb/innovation/our-leading-scientists/dr-christopher-austin/","nodes":[],"isActive":false},{"title":"Charlotte Allerton","url":"/en-gb/innovation/our-leading-scientists/charlotte-allerton/","nodes":[],"isActive":false},{"title":"Dr Sanjay Gurunathan","url":"/en-gb/innovation/our-leading-scientists/dr-sanjay-gurunathan/","nodes":[],"isActive":false}],"isActive":false},{"title":"Research and development approach","url":"/en-gb/innovation/research-and-development-approach/","nodes":[],"isActive":false},{"title":"Pipeline","url":"/en-gb/innovation/pipeline/","nodes":[],"isActive":false},{"title":"Tech","url":"/en-gb/innovation/technologies/","nodes":[{"title":"Post-quantum cryptography","url":"/en-gb/innovation/technologies/post-quantum-cryptography/","nodes":[],"isActive":false}],"isActive":false},{"title":"Clinical trials at GSK","url":"/en-gb/innovation/trials/","nodes":[{"title":"Provision of unapproved medicines for unmet medical needs","url":"/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/","nodes":[],"isActive":false},{"title":"Data transparency","url":"/en-gb/innovation/trials/data-transparency/","nodes":[],"isActive":false},{"title":"Representative clinical studies","url":"/en-gb/innovation/trials/representative-clinical-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"Partnering with GSK","url":"/en-gb/innovation/partnerships/","nodes":[{"title":"Supported studies","url":"/en-gb/innovation/partnerships/supported-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"R&D locations","url":"/en-gb/innovation/rd-locations/","nodes":[{"title":"Flagship R&D centre in Cambridge, UK","url":"/en-gb/innovation/rd-locations/flagship-rd-centre-in-cambridge-uk/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130&hmac=c3e21840aa4184183d7a56b6b9e51c276f4c0cfa99faddf0b2e96abade984999","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130&hmac=1ee1d1cba0cbe920daab92982b410dfd5be6b812ffb18d46bc5a1b15dc8ea9e4","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Our leading scientists","image":{"src":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=100&v=1dc651e856734f0&hmac=89240d0220a7a43a3ae9394fb29afbab3cb4192dc9283cc81575d646ff2c2d97","alt":"Tony Wood","darkModeSrc":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=50&v=1dc651e856734f0&hmac=aa2617bc227baad2755a0fb9ad1fbe695d7cd6bbae99b54a174e6ece08ac6f3f","fileSize":""},"link":{"text":"Featured section","href":"/en-gb/innovation/our-leading-scientists/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-gb/products/","nodes":[{"title":"Product areas","url":"/en-gb/products/our-product-areas/","nodes":[],"isActive":false},{"title":"Products A-Z","url":"/en-gb/products/products-a-z/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Innovation","image":{"src":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe22d650&hmac=7e7c4f7e55d1c5f8195a127fe9f281066fa29131749b341d38ddb0d073a8c08e","alt":"Lab technician leaning against wall","darkModeSrc":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe22d650&hmac=a094b899394c4bc9edc97886a222232920b438f99f396aadeb7e3b2848f7ee89","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/","openInNewWindowText":null}},{"text":"GSKPro for healthcare professionals ","image":{"src":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe35c210&hmac=2075d37c23b475f2bc9ac77a07adcafcd381777fce6f7d574009e72fff69ff1f","alt":"Two scientists on orange background","darkModeSrc":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe35c210&hmac=e50f7e49e96007544857017de5b32764327c6f3fd6d677c14972001d3b9771c4","fileSize":""},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-gb/responsibility/","nodes":[{"title":"Access","url":"/en-gb/responsibility/access/","nodes":[],"isActive":false},{"title":"Global health and health security","url":"/en-gb/responsibility/global-health-and-health-security/","nodes":[{"title":"Global health","url":"/en-gb/responsibility/global-health-and-health-security/global-health/","nodes":[],"isActive":false},{"title":"Health security","url":"/en-gb/responsibility/global-health-and-health-security/health-security/","nodes":[],"isActive":false},{"title":"Using our science for global health","url":"/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/","nodes":[],"isActive":false},{"title":"Africa Open Lab","url":"/en-gb/responsibility/global-health-and-health-security/africa-open-lab/","nodes":[],"isActive":false}],"isActive":false},{"title":"Environment","url":"/en-gb/responsibility/environment/","nodes":[{"title":"Climate","url":"/en-gb/responsibility/environment/climate/","nodes":[],"isActive":false},{"title":"Freshwater","url":"/en-gb/responsibility/environment/freshwater/","nodes":[],"isActive":false},{"title":"Land","url":"/en-gb/responsibility/environment/land/","nodes":[],"isActive":false},{"title":"Oceans","url":"/en-gb/responsibility/environment/oceans/","nodes":[],"isActive":false},{"title":"Materials and waste","url":"/en-gb/responsibility/environment/materials-and-waste/","nodes":[],"isActive":false},{"title":"Health system sustainability","url":"/en-gb/responsibility/environment/health-system-sustainability/","nodes":[],"isActive":false}],"isActive":false},{"title":"Inclusion","url":"/en-gb/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-gb/responsibility/ethical-standards/","nodes":[{"title":"Working with third parties","url":"/en-gb/responsibility/ethical-standards/working-with-third-parties/","nodes":[],"isActive":false},{"title":"Public policy and patient advocacy","url":"/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","nodes":[],"isActive":false},{"title":"Human rights","url":"/en-gb/responsibility/ethical-standards/human-rights/","nodes":[],"isActive":false},{"title":"Use of animals","url":"/en-gb/responsibility/ethical-standards/use-of-animals/","nodes":[],"isActive":false},{"title":"Engaging with healthcare professionals","url":"/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false}],"isActive":false},{"title":"Product governance","url":"/en-gb/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-gb/responsibility/grants-and-donations/","nodes":[],"isActive":false},{"title":"Charitable investments ","url":"/en-gb/responsibility/charitable-investments/","nodes":[],"isActive":false},{"title":"Responsibility reports","url":"/en-gb/responsibility/responsibility-reports/","nodes":[{"title":"Reports archive","url":"/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030&hmac=12ac7ded8bd7ab6e4665214fcc035ed44c079abcb2fbda20ea2220be73c1f12e","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030&hmac=a50405e6d858c131f8bc642c26ae3a9fb06154803458a748320a0ff3ec9c7e2f","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}},{"text":"Our policy positions","image":{"src":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe9b61b0&hmac=9e323e7d55541fa849cbe984c44f8a60da1e99fe2119d3c3fb9efb2dda7b58a8","alt":"GSK orange texture","darkModeSrc":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe9b61b0&hmac=322065363b28083d211d5e68d0cffdbb01a506045f8e286c0284e908ea0a5805","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/company/policy-positions/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Investors","url":"/en-gb/investors/","nodes":[{"title":"Why invest in GSK?","url":"/en-gb/investors/why-invest-in-gsk/","nodes":[],"isActive":false},{"title":"Quarterly results","url":"/en-gb/investors/quarterly-results/","nodes":[],"isActive":false},{"title":"Financial reports","url":"/en-gb/investors/financial-reports/","nodes":[{"title":"Annual Report 2025","url":"/en-gb/investors/financial-reports/annual-report-2025/","nodes":[],"isActive":false},{"title":"Corporate reports archive","url":"/en-gb/investors/financial-reports/corporate-reports-archive/","nodes":[],"isActive":false}],"isActive":false},{"title":"Responsible business","url":"/en-gb/investors/responsible-business/","nodes":[],"isActive":false},{"title":"Speeches and presentations","url":"/en-gb/investors/speeches-and-presentations/","nodes":[],"isActive":false},{"title":"Science publications","url":"/en-gb/investors/science-publications/","nodes":[],"isActive":false},{"title":"Events calendar","url":"/en-gb/investors/events-calendar/","nodes":[],"isActive":false},{"title":"Dividend and share price","url":"/en-gb/investors/dividend-and-share-price/","nodes":[{"title":"GSK share price","url":"/en-gb/investors/dividend-and-share-price/gsk-share-price/","nodes":[],"isActive":false},{"title":"Share price calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calendar","url":"/en-gb/investors/dividend-and-share-price/dividend-calendar/","nodes":[],"isActive":false}],"isActive":false},{"title":"Analyst consensus","url":"/en-gb/investors/analyst-consensus/","nodes":[],"isActive":false},{"title":"Stock exchange announcements","url":"/en-gb/investors/stock-exchange-announcements/","nodes":[{"title":"London (RNS)","url":"/en-gb/investors/stock-exchange-announcements/london-rns/","nodes":[],"isActive":false},{"title":"London (RNS) inside information","url":"/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/","nodes":[],"isActive":false},{"title":"New York (SEC)","url":"/en-gb/investors/stock-exchange-announcements/new-york-sec/","nodes":[],"isActive":false},{"title":"Sign up for announcements","url":"/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/","nodes":[],"isActive":false}],"isActive":false},{"title":"Shareholder information","url":"/en-gb/investors/shareholder-information/","nodes":[{"title":"Manage your shares","url":"/en-gb/investors/shareholder-information/manage-your-shares/","nodes":[],"isActive":false},{"title":"Annual General Meeting","url":"/en-gb/investors/shareholder-information/annual-general-meeting/","nodes":[],"isActive":false},{"title":"General Meeting","url":"/en-gb/investors/shareholder-information/general-meeting/","nodes":[],"isActive":false},{"title":"Annual Governance Meeting","url":"/en-gb/investors/shareholder-information/annual-governance-meeting/","nodes":[],"isActive":false},{"title":"Corporate sponsored nominee service","url":"/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/","nodes":[],"isActive":false},{"title":"Our ADR programme","url":"/en-gb/investors/shareholder-information/adr-programme/","nodes":[],"isActive":false},{"title":"Asset reunification - Georgeson   ","url":"/en-gb/investors/shareholder-information/asset-reunification-georgeson/","nodes":[],"isActive":false},{"title":"Share scam alert","url":"/en-gb/investors/shareholder-information/share-scam-alert/","nodes":[],"isActive":false},{"title":"Privacy notice for ordinary shareholders","url":"/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/","nodes":[],"isActive":false},{"title":"FAQs","url":"/en-gb/investors/shareholder-information/shareholder-faqs/","nodes":[],"isActive":false}],"isActive":false},{"title":"Corporate actions","url":"/en-gb/investors/corporate-actions/","nodes":[{"title":"Consumer Healthcare Demerger","url":"/en-gb/investors/corporate-actions/consumer-healthcare-demerger/","nodes":[],"isActive":false},{"title":"Consumer Healthcare Joint Venture","url":"/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/","nodes":[],"isActive":false},{"title":"Agreement to acquire TESARO","url":"/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/","nodes":[],"isActive":false}],"isActive":false},{"title":"Debt investors","url":"/en-gb/investors/debt-investors/","nodes":[],"isActive":false},{"title":"Investor contacts","url":"/en-gb/investors/investor-contacts/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Press releases","image":{"src":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc6f12bb0&hmac=f3dda3c7bd6599a1c2f05133bb899c647be6962b177d4b772cd87d676c8a7d94","alt":"Lab machinery","darkModeSrc":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc6f12bb0&hmac=39e1b2702e8059aa94f14c98a803dbe514bde3cb0ae2d3d2fd23a6e78c938b52","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/media/press-releases/","openInNewWindowText":null}},{"text":"Our pipeline","image":{"src":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc701f490&hmac=bf2488fd39b58115ffca972c3b022be99778cb82fc5a894714dd3d84863ed736","alt":"Case of vials","darkModeSrc":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc701f490&hmac=31c09472f1b12264f8141bef8b943a0354c076daf5ec330cb2322259c29365b9","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/pipeline/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-gb/media/","nodes":[{"title":"Press releases","url":"/en-gb/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-gb/media/media-contacts/","nodes":[],"isActive":false},{"title":"Media statements","url":"/en-gb/media/media-statements/","nodes":[],"isActive":false},{"title":"Media library","url":"/en-gb/media/media-library/","nodes":[],"isActive":false},{"title":"Our social media","url":"/en-gb/media/social-media/","nodes":[],"isActive":false},{"title":"Podcasts","url":"/en-gb/media/podcasts/","nodes":[],"isActive":false},{"title":"RSS feeds","url":"/en-gb/media/rss-feeds/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Behind the Science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130&hmac=c3e21840aa4184183d7a56b6b9e51c276f4c0cfa99faddf0b2e96abade984999","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130&hmac=1ee1d1cba0cbe920daab92982b410dfd5be6b812ffb18d46bc5a1b15dc8ea9e4","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Podcasts","image":{"src":"/media/tifb3jbw/bts-podcast-cover.jpg?rxy=0.3396812535345467,0.7098154172768643&width=329&height=185&format=webp&quality=100&v=1dc8ade65132ac0&hmac=8516fcec0699f0af4c0d1d3a3cb506fb47fd5a221d6a501a81eeb2c68f1c1998","alt":"Behind the science podcast cover ","darkModeSrc":"/media/tifb3jbw/bts-podcast-cover.jpg?rxy=0.3396812535345467,0.7098154172768643&width=329&height=185&format=webp&quality=50&v=1dc8ade65132ac0&hmac=e1517c1889bf48d5e31af2d9cfabe3dfbeee773f9a250a984d718db749944c52","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/media/podcasts/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-gb/careers/","nodes":[{"title":"Search jobs","url":"/en-gb/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Featured careers","url":"/en-gb/careers/featured-careers/","nodes":[{"title":"A career in data","url":"/en-gb/careers/featured-careers/a-career-in-data/","nodes":[],"isActive":false}],"isActive":false},{"title":"Life at GSK","url":"/en-gb/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Outstanding people","url":"/en-gb/careers/outstanding-people/","nodes":[{"title":"Great place to work","url":"/en-gb/careers/outstanding-people/great-place-to-work/","nodes":[],"isActive":false},{"title":"Meet our veterans","url":"/en-gb/careers/outstanding-people/meet-our-veterans/","nodes":[],"isActive":false},{"title":"Working together","url":"/en-gb/careers/outstanding-people/working-together/","nodes":[],"isActive":false},{"title":"My GSK story","url":"/en-gb/careers/outstanding-people/my-gsk-story/","nodes":[],"isActive":false},{"title":"Innovating together","url":"/en-gb/careers/outstanding-people/innovating-together/","nodes":[],"isActive":false}],"isActive":false},{"title":"Experienced professionals","url":"/en-gb/careers/experienced-professionals/","nodes":[{"title":"Business operations","url":"/en-gb/careers/experienced-professionals/business-operations/","nodes":[],"isActive":false},{"title":"Engineering at GSK ","url":"/en-gb/careers/experienced-professionals/engineering/","nodes":[],"isActive":false},{"title":"Global supply chain","url":"/en-gb/careers/experienced-professionals/global-supply-chain/","nodes":[],"isActive":false},{"title":"Sales and marketing","url":"/en-gb/careers/experienced-professionals/sales-and-marketing/","nodes":[],"isActive":false},{"title":"Research and development","url":"/en-gb/careers/experienced-professionals/research-and-development/","nodes":[{"title":"Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)","url":"/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/","nodes":[],"isActive":false},{"title":"Genomic sciences","url":"/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/","nodes":[],"isActive":false}],"isActive":false},{"title":"Technology","url":"/en-gb/careers/experienced-professionals/technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-gb/careers/early-careers/","nodes":[{"title":"Application process","url":"/en-gb/careers/early-careers/application-process/","nodes":[],"isActive":false},{"title":"Apprentice programmes","url":"/en-gb/careers/early-careers/apprentice-programmes/","nodes":[],"isActive":false},{"title":"Internships and placements","url":"/en-gb/careers/early-careers/internships-and-placements/","nodes":[],"isActive":false},{"title":"Graduate programme","url":"/en-gb/careers/early-careers/graduate-programme/","nodes":[{"title":"Business operations","url":"/en-gb/careers/early-careers/graduate-programme/business-operations/","nodes":[],"isActive":false},{"title":"Engineering","url":"/en-gb/careers/early-careers/graduate-programme/engineering/","nodes":[],"isActive":false},{"title":"Manufacturing & supply","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/","nodes":[],"isActive":false},{"title":"Commercial ","url":"/en-gb/careers/early-careers/graduate-programme/commercial/","nodes":[],"isActive":false},{"title":"Research & development","url":"/en-gb/careers/early-careers/graduate-programme/research-development/","nodes":[],"isActive":false},{"title":"Manufacturing sciences & technology","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Post graduate opportunities","url":"/en-gb/careers/early-careers/post-graduate-opportunities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/early-careers/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans","url":"/en-gb/careers/veterans/","nodes":[],"isActive":false},{"title":"Our global and regional hubs","url":"/en-gb/careers/our-global-and-regional-hubs/","nodes":[],"isActive":false},{"title":"How we hire","url":"/en-gb/careers/how-we-hire/","nodes":[{"title":"Fraudulent internet recruitment activities","url":"/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/how-we-hire/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0&hmac=9e8e9da5bd3ca0619cfd47c6274f5ecbae61a5b73808bbd57b4fdffa469f2037","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0&hmac=25f6331ff89b8ea1f896e23e1cc935cee241b346efb1b08bd5aa5b5aa0d4e09c","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/careers/outstanding-people/","openInNewWindowText":null}},{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030&hmac=12ac7ded8bd7ab6e4665214fcc035ed44c079abcb2fbda20ea2220be73c1f12e","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030&hmac=a50405e6d858c131f8bc642c26ae3a9fb06154803458a748320a0ff3ec9c7e2f","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}}]}],"skipToContent":"Skip to content","skipToSearch":"Skip to search","typeaheadSearch":{"endpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"Enter a search term...","searchButtonText":"Search","searchPage":"/en-gb/search/","ariaLabel":"Submit form","suggestedSearchEnabled":true,"suggestedSearchResultsEnabled":true,"suggestedSearchLabel":"Suggested search","suggestedResultsLabel":"Suggested results","noResultsText":"No results found","suggestedSearchNoResultsText":"We don't have any suggestions to your search input. Please try a different search.","resultTagColour":"#00b8ad","mostPopular":{"label":"Most popular searches","items":[{"text":"Quarterly results","url":"/en-gb/search/?q=Quarterly%20results"},{"text":"Vaccines","url":"/en-gb/search/?q=Vaccines"},{"text":"Pipeline","url":"/en-gb/search/?q=Pipeline"},{"text":"Behind the science","url":"/en-gb/search/?q=Behind%20the%20science"},{"text":"Careers","url":"/en-gb/search/?q=Careers"},{"text":"GSK at a glance","url":"/en-gb/search/?q=GSK%20at%20a%20glance"},{"text":"Podcasts","url":"/en-gb/search/?q=Podcasts"}]}},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"<p>This is our global website, intended for visitors seeking information on GSK's worldwide business.&nbsp; Our market sites can be reached by visiting our <a href=\"/en-gb/locations/\" title=\"Location selector\">location selector.&nbsp;</a>&nbsp;</p>\n<p>&nbsp;</p>\n<p>© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.</p>\n<p>GSK plc. Registered in England and Wales No. 3888792.</p>\n<p>Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG</p>","modernSlaveryStatement":{"name":"Modern Slavery Act Statement 2025","url":"/media/5ladhmeu/modern-slavery-act-statement-2025.pdf","fileExtension":"PDF","fileSize":"187.7KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Linkedin","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"http://twitter.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK X page","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":"Visit GSK on Bluesky","href":"https://bsky.app/profile/gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Bluesky","customIcon":null,"showPopupMenu":false,"type":"Bluesky"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Facebook page","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK YouTube Channel","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"/en-gb/media/rss-feeds/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Visit GSK RSS feeds","customIcon":null,"showPopupMenu":false,"type":"Rss"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"Locations selector","href":"/en-gb/locations/","openInNewWindowText":null},{"text":"Social media directory","href":"/en-gb/media/social-media/","openInNewWindowText":null},{"text":"GSKPro for healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-gb/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-gb/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-gb/responsibility/","openInNewWindowText":null},{"text":"Investors","href":"/en-gb/investors/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-gb/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},{"text":"Partnerships","href":"/en-gb/innovation/partnerships/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-gb/contact-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-gb/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-gb/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-gb/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-gb/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-gb/privacy-notice/general","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-gb/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"GSK announced that dosing has commenced in a phase III study evaluating sirukumab.","og":[{"property":"og:title","content":"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis"},{"property":"og:description","content":"GSK announced that dosing has commenced in a phase III study evaluating sirukumab."},{"property":"og:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530&hmac=ab24aca71bcd831e94bc74c882b7abfdb757d8f146e8db21ae52c0375a0fd10d"},{"property":"og:url","content":"https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis"},{"name":"twitter:description","content":"GSK announced that dosing has commenced in a phase III study evaluating sirukumab."},{"name":"twitter:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530&hmac=ab24aca71bcd831e94bc74c882b7abfdb757d8f146e8db21ae52c0375a0fd10d"},{"name":"twitter:url","content":"https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":false,"title":"","texts":"","continueText":"Continue","cancelText":"Cancel","exclusionUrls":[]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=100&v=1dbf4b05a4e6470&hmac=88eee08ffc4c7e7b930ebd265a76bc829fe24564389a8e6d463f844dfe83fef8","alt":"Gsk Logo","darkModeSrc":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=50&v=1dbf4b05a4e6470&hmac=994d785e3ecfaac6bc9c67bacc48b0c287fa77e4c4f0d3de82d33bb48be5efda","fileSize":""},"scripts":[{"pageLocation":"Top","text":"<!-- Loading script asynchronously -->  \n<script type='text/javascript'>  (function(a,b,c,d){     a='//tags.tiqcdn.com/utag/gsk/profile-rx-gb/prod/utag.js' ; b=document;c='script';d=b.createElement(c);d.src=a;d.type='text/java'+c;d.async=true;    a=b.getElementsByTagName(c)[0];a.parentNode.insertBefore(d,a);  })();  </script>"}],"globalWebsiteLink":null,"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":{"title":"","text":"<p>You are about to access GSK historic archived press release material retained as a corporate record. References to products or their uses may be out of date and not reflect current medical, safety or regulatory information. For clinical information, consult the approved national product label information (SmPC).</p>","continueText":"Continue","cancelText":"Cancel"},"protectedPage":false,"schema":{"jsonLdSchemas":["{\"@context\":\"https://schema.org\",\"@type\":\"NewsArticle\",\"description\":\"GSK announced that dosing has commenced in a phase III study evaluating sirukumab.\",\"mainEntityOfPage\":\"https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/\",\"author\":{\"@type\":\"Organization\",\"name\":\"GSK\",\"url\":\"https://www.gsk.com/en-gb/\"},\"datePublished\":\"2015-11-25T00:00:00+00:00\",\"headline\":\"GSK announces start of phase III study of sirukumab in Giant Cell Arteritis\",\"keywords\":\"Medicines,Research and development\",\"articleSection\":\"Press releases\"}"]}}